While a new or future treatment for ATTR-CM can improve your condition, it may also come with an extraordinary price tag. Retail prices of the ATTR-CM therapies currently on the market range from $100,000 to $500,000 and above for a one-year supply. While very few patients pay the full cost out of pocket, the price can be considerable even for those with excellent insurance, and not everyone will be able to access these medications.
“Patients are certainly paying thousands of dollars, which is pretty significant, considering that this is a lifelong therapy,” DiDomenico says.
There is some evidence that less expensive therapies such as doxycycline plus ursodiol, tauroursodeoxycholic acid, and even green tea extract can have positive effects for ATTR-CM, but Alexander says that these are not effective stand-ins for tafamidis, acoramidis, or vutrisiran.
“I don’t view these things as alternatives,” he says. “They have been looked at in small studies, but those aren’t the same kind of large, randomized, controlled trials that we have for FDA-approved drugs.”
Share your financial concerns with members of your cardiology team. They can guide you toward resources for navigating your insurance coverage or accessing patient assistant or discount programs.
Read the full article here
